Corgard (nadolol)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Nadolol is a nonselective beta-adrenergic blocking agent (beta-blocker).
Nadolol is used for the management of hypertension and angina. Nadolol has been used for the management of supraventricular tachyarrhythmias (e.g., atrial flutter or fibrillation+) and for the prophylaxis of sinus headache+.
Generic name: nadolol
Pronunciation: (NAY-doe-lol)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Corgard
Indications
The following indications are listed for Corgard:
- Hypertension
- Prevention Of Anginal Pain Associated With Coronary Artery Disease
Also known as: Elevated Blood Pressure, Essential Hypertension, Hyperpiesia, Hyperpiesis, Hypertensive Disorder, Prevention Of Anginal Pain Associated With Cad, Systemic Arterial Hypertension.
Dosing
Since there is no consistent interpatient correlation between the dosage of nadolol and therapeutic response, dosage must be individualized according to the response of the patient. If long-term nadolol therapy is to be discontinued, dosage of the drug should be gradually reduced over a period of 1-2 weeks. (See Cautions: Precautions and Contraindications.)
In patients with renal impairment, the usual dose of nadolol alone or in fixed combination with bendroflumethiazide is given at the following intervals depending on the patient's creatinine clearance (see Table):
Table. Dosage in Renal Impairment.
Creatinine Clearance (mL/minute per Dosage Interval 1.73 m2) >50 every 24 h 31-50 every 24-36 h 10-30 every 24-48 h <10 every 40-60 h
Nadolol is administered orally once daily.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Although some of the drug interactions that have occurred with propranolol have not been reported to date during nadolol therapy, it should be kept in mind that nadolol and propranolol have similar pharmacologic effects and probably have similar drug interactions.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Nadolol has been shown to be embryotoxic and fetotoxic in rabbits, but not in rats or hamsters, when given at dosages 5-10 times the maximum recommended human dosage; no teratogenic potential was observed in any of these species. There are no adequate and well-controlled studies using nadolol in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. Neonates whose mothers were receiving nadolol at parturition have exhibited bradycardia, hypoglycemia, and associated symptoms.
Nadolol is distributed into milk. Because of the potential for adverse reactions to nadolol in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.